U.S. chooses Texas A&M bio-manufacturing center for production of COVID-19 vaccine candidates

Date Published07/27/2020
Author NameThalia Brionez
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name FUJIFILM Diosynth Biotechnologies, Texas, (FDB)
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
Capital investment ($):265
Country(ies) from which reshored:Japan
City reshored to:College Station
State(s) reshored to:TX
If relevant, work nearshored to:-
Product(s) reshoredCovid-19 vaccine candidate NVX-CoV2373
What non-domestic negative factors made offshoring less attractive?Loss of control
What domestic positive factors made reshoring more attractive?Government Incentives, Covid-19
Government Incentive dollar amount:$265 million
Find Reshoring Articles